Small Molecules
25 January 2016
Alkermes Announces Initiation of Phase 1 Clinical Study of New CNS Drug Candidate ALKS 711925 January 2016
Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline25 January 2016
U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)22 January 2016
Janssen Research & Development, LLC Voluntarily Suspends Dosing in Phase 2 Clinical Trials of Experimental Treatment for Mood Disorders22 January 2016
Oncoceutics Begins Fifth Clinical Trial for ONC20122 January 2016
Oxeia Biopharmaceuticals, Inc. Advancing Development Of OXE-103 For The Treatment Of Concussions21 January 2016
Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD21 January 2016
vasopharm Announces EUR 20 Million Fundraising to Progress Treatment for Traumatic Brain Injury21 January 2016
vTv Therapeutics Initiates Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes21 January 2016
Alkermes Announces Topline Results of FORWARD-3 and FORWARD-4, Two Phase 3 Studies of ALKS 5461 in Major Depressive Disorder20 January 2016
Delcath Announces Initiation Of Phase 3 Trial Of Melphalan/HDS System For Treatment Of Hepatic Dominant Ocular Melanoma20 January 2016
Zafgen’s Pivotal Phase 3 Trial of Beloranib in Prader-Willi Syndrome Achieves Co-Primary Efficacy Endpoints19 January 2016
Aclaris Therapeutics Initiates Phase 3 Clinical Trials of A-101 for the Treatment of Seborrheic Keratosis19 January 2016
Rapastinel (GLYX-13) Shown to Improve Ketamine or PCP-Induced Cognitive Impairment in Mice19 January 2016
UCB’s new epilepsy drug BRIVIACT® receives EU approval19 January 2016
Neurelis Initiates Pivotal Clinical Program for NRL-1 in the Treatment of Acute Repetitive Seizures19 January 2016
Trevena, Inc. Announces Initiation of Oliceridine Phase 3 Clinical Program With Multi-Procedure Safety and Tolerability Study18 January 2016
U.S. FDA accepts for priority review sNDA for Eisai’s anticancer agent lenvatinib seeking approval for renal cell carcinomaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports